Comparative evaluation of efficacy and safety between conventional transarterial chemoembolization (cTACE) using Lipiodol and drug-eluting bead TACE (DEB-TACE) in patients with hepatocellular carcinoma: A retrospective study
Aristotle University of Thessaloniki · 01.01.2026
DOI: 10.26262/heal.auth.ir.373874 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aristotle University of Thessaloniki, erschienen am 01.01.2026. Verfasst von Μαρία Α. Ζήδρου.
Abstract (Originalsprache)
Background
Hepatocellular carcinoma (HCC) is the most common primary malignant liver tumor. Transarterial chemoembolization (TACE) is the standard locoregional therapy for intermediate-stage, unresectable HCC. The main techniques are conventional TACE (cTACE) and drug-eluting bead TACE (DEB-TACE); however, there is no consensus on which method is clinically superior.
Aim
To compare the efficacy and safety of cTACE and DEB-TACE in patients with unresectable primary HCC. Materials and Methods: This retrospective single-center study was conducted at a tertiary Greek hospital between February 2019 and September 2025. It included consecutive adults with primary HCC (BCLC A-C) treated exclusively with cTACE or DEB-TACE; patients receiving other locoregional or systemic therapies, surgery, or those with severe comorbidities were excluded. The primary outcome was overall survival (OS), measured from the first TACE to death or last confirmed follow-up, via electronic archives. Secondary outcomes included 3- and 6-month tumor response, evaluated using CT/MRI, and adverse events within one month, recorded during a follow-up call. Statistical analysis included survival assessment with Kaplan-Meier curves and log-rank tests, and due to non- proportional hazards, Restricted Mean Survival Test (RMST) and Multiple-Direction Weighted Log-Rank (MDIR) test. Secondary outcomes were compared using Chi-square, Fisher’s exact tests, or logistic regression when appropriate. The study was approved by the Institutional Ethics Committee.
Results
The study population included 50 patients (30 cTACE, 20 DEB-TACE). The log rank test (p = 0.56) and MDIR test (p = 0.11) both showed no significant difference in OS between the two groups. RMST demonstrated a significant survival benefit for DEB-TACE at 24 months (difference 4.39 months, p = 0.03), while other intervals were non-significant. Tumor response at 3 months (χ², p = 0.907), 6 months (Fisher’s exact, p = 0.467), and any (χ², p = 0.904) or severe adverse events (χ², p = 0.065) did not differ significantly between groups. Treatment modality was not an independent predictor of 3-month response on logistic regression (p = 0.186).
Conclusion
This thesis indicated an early survival benefit for DEB-TACE, with comparable long-term efficacy and safety to cTACE, supporting individualized selection of either technique based on patient and disease profiles.
Schlagwörter
Zitieren
APA
Ζήδρου, Μ. Α. (2026). Comparative evaluation of efficacy and safety between conventional transarterial chemoembolization (cTACE) using Lipiodol and drug-eluting bead TACE (DEB-TACE) in patients with hepatocellular carcinoma: A retrospective study. Aristotle University of Thessaloniki. https://doi.org/10.26262/heal.auth.ir.373874
Vancouver
Ζήδρου ΜΑ. Comparative evaluation of efficacy and safety between conventional transarterial chemoembolization (cTACE) using Lipiodol and drug-eluting bead TACE (DEB-TACE) in patients with hepatocellular carcinoma: A retrospective study. Aristotle University of Thessaloniki. 2026. doi:10.26262/heal.auth.ir.373874
BibTeX
@article{2026,
author = {Ζήδρου, Μαρία Α.},
title = {Comparative evaluation of efficacy and safety between conventional transarterial chemoembolization (cTACE) using Lipiodol and drug-eluting bead TACE (DEB-TACE) in patients with hepatocellular carcinoma: A retrospective study},
journal = {Aristotle University of Thessaloniki},
year = {2026},
doi = {10.26262/heal.auth.ir.373874}
}
EUVIMED